Sort   by:  
 Page size 
UnknownA multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Not available
S-EPMC4186779 | biostudies-literature
UnknownIdentification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity.
Not available
S-EPMC2323188 | biostudies-literature
UnknownIdentification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Not available
S-EPMC3952546 | biostudies-literature
UnknownEmerging therapies for acute myeloid leukemia: translating biology into the clinic.
Not available
S-EPMC5621868 | biostudies-literature
UnknownDesign, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.
Not available
S-EPMC3151534 | biostudies-literature
UnknownAcute myeloid leukemia drug-tolerant persister cells survive chemotherapy by transiently increasing plasma membrane rigidity, that also increases their sensitivity to immune cell killing.
Not available
S-EPMC11962361 | biostudies-literature
UnknownElevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis.
Not available
S-EPMC12003737 | biostudies-literature
UnknownGenomic profiles and outcomes in de novo versus therapy-related core binding factor AML.
Not available
S-EPMC11528045 | biostudies-literature
UnknownA Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
Not available
S-EPMC5119957 | biostudies-literature
UnknownWho truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.
Not available
S-EPMC12378385 | biostudies-literature
Sort   by:  
 Page size